Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cassava Sciences Inc
(NQ:
SAVA
)
30.39
-0.91 (-2.91%)
Streaming Delayed Price
Updated: 12:51 PM EDT, Sep 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Cassava Sciences Inc
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
20
21
Next >
Why Cortexyme Thinks It Could Be Next In The Mega Alzheimer's Drug Market
October 21, 2021
Cortexyme is testing a twice-day pill to treat Alzheimer's disease.
Via
Investor's Business Daily
3 Biotech Stocks That Are Ridiculously Overpriced
October 20, 2021
They've risen too far, too quickly.
Via
The Motley Fool
It Turns Out That The World Still Needs Coal: Good News For Our Recent Top Name, Peabody Energy
October 19, 2021
A Liebherr mining truck at dusk at Peabody's North Antelope Rochelle Mine in the Powder River Basin of Wyoming (photo via Peabody). It Turns Out The World...
Via
Benzinga
It Turns Out The World Still Needs Coal
October 19, 2021
Peabody Energy (BTU), whose shares spiked 23% on Monday after the company announced that its coal revenue in Q3 would be the highest in seven quarters and it offered bullish forward guidance.
Via
Talk Markets
Exposures
Coal
Crisis Investing
October 12, 2021
From COVID, to energy, to supply chain breakdowns, the market has been buffeted by crises recently. How we've navigated them so far.
Via
Talk Markets
Crisis Investing: From COVID, To Energy, To Supply Chain Breakdowns, The Market Has Been Buffeted By Crises Recently. How We've Navigated Them So Fa.
October 12, 2021
A Gadsden flag hung out of a Southwest Airlines 737 cockpit. Photo via American Greatness. A Market Buffeted By Bad News The apparent work slowdown at...
Via
Benzinga
Exposures
Labor
Cassava Sciences: Fine Trading Stock, Terrible Investment
October 11, 2021
SAVA stock may be fun to trade, but the long-term prognosis is grim
Via
InvestorPlace
Topics
Fraud
Exposures
Legal
Cassava Sciences Starts Late-Stage Simufilam Study In Alzheimer's Patients
October 06, 2021
Cassava Sciences Inc (NASDAQ: SAVA) initiated an initial Phase 3 efficacy study of simufilam, an investigational drug for patients with Alzheimer's disease....
Via
Benzinga
Cassava Sciences Stock Could Explode as FDA Approval Is a Real Possibility
October 06, 2021
SAVA stock is volatile but worthwhile as its Alzheimer's drug inches closer to commercialization. Risk tolerance is needed, though.
Via
InvestorPlace
Exposures
Product Safety
Rebuilding Connections, Fostering Growth: Synaptogenix Could Be A Beacon of Hope for Patients With Neurological Diseases
October 05, 2021
Image by Gerd Altmann from Pixabay How well we think, feel and act rests in the hands of trillions of tiny connectors in our minds. Synapses play an integral role in how we...
Via
Benzinga
How David Green Traded Moderna For A Big Profit On Monday Morning
October 04, 2021
David Green was back live trading on Benzinga TV on Monday morning. Here's a recap of what he traded and discussed. Big Winners Of The Day Green's best trade on...
Via
Benzinga
Use Cassava Sciences Stock Weakness as Buy Opportunity Ahead of Phase 3
October 04, 2021
If Cassava Sciences' Alzheimer drug can continue to produce solid results, it could see FDA approval before the end of 2022. SAVA stock may not be oversold for long.
Via
InvestorPlace
Exposures
Product Safety
What to Make of Cassava Sciences’ Late September Rally
October 04, 2021
Cassava Sciences gained 50% in the second half of September. Now the question is, can SAVA stock keep up momentum in October?
Via
InvestorPlace
Cassava Stock Has Reached a Positive Turning Point
October 01, 2021
Cassava is rebounding and SAVA stock may rally back to its old highs as it fends off a short-selling attack.
Via
InvestorPlace
The Good News Is Piling Up for Cassava Stock
October 01, 2021
Recent news indicates that the FDA is going to reject a petition against Cassava, helping to make SAVA stock very attractive.
Via
InvestorPlace
Exposures
Product Safety
Is Cassava Sciences Back in the Game?
September 28, 2021
There's nothing spectacular about the latest results for the company's flagship drug.
Via
The Motley Fool
12 Health Care Stocks Moving In Friday's Intraday Session
September 24, 2021
Gainers Molecular Templates (NASDAQ:MTEM) stock rose 14.13% to $7.59 during Friday's regular session. Trading volume for Molecular Templates's stock is 937.9K as...
Via
Benzinga
Why Shares of Cassava Sciences Rose 15% Today
September 23, 2021
Additional data is promising. But will investors trust it?
Via
The Motley Fool
B. Riley Says Alzheimer's Data From This Firm Has Renewed 'Investor Confidence'
September 23, 2021
B. Riley says yesterday's readout from a pre-planned 12-month treatment interim analysis of Cassava Sciences Inc's (NASDAQ: SAVA) simufilam trial data...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
September 23, 2021
Gainers TransCode Therapeutics (NASDAQ:RNAZ) stock rose 94.3% to $5.09 during Thursday's regular session. TransCode Therapeutics's stock is trading at a volume of...
Via
Benzinga
58 Biggest Movers From Yesterday
September 24, 2021
Gainers MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) shares surged 73.4% to close at $12.80 on Thursday following news the company will buy ZACC Kabushiki Kaisha for $3.362...
Via
Benzinga
SAVA Stock: What Is Going on With Red-Hot Cassava Sciences Today?
September 22, 2021
Today, Cassava Sciences initially soared on the announcement of some positive preliminary data, before SAVA stock began selling off.
Via
InvestorPlace
The Cassava Sciences Saga Rages On — Why This Alzheimer's Update Didn't Save It
September 22, 2021
Cassava said patients who received its Alzheimer's drug showed improved cognition.
Via
Investor's Business Daily
Cassava Sciences' Simufilam Data Shows Improved Cognition In Alzheimer's Disease
September 22, 2021
Cassava Sciences Inc (NASDAQ: SAVA) has announced top-line data from a pre-planned interim analysis of an ongoing open-label study of simufilam in mild-to-moderate...
Via
Benzinga
Cassava Sciences Can Recover Despite Harsh Allegations
September 21, 2021
SAVA stock dove after a law firm made statements against the company. However, Cassava's CEO isn't just taking it lying down.
Via
InvestorPlace
The Cassava Saga: Here's What You Need To Know About This Embattled Alzheimer's Stock
September 21, 2021
Cassava Sciences could hold the holy grail in Alzheimer's treatment. But once highflying SAVA stock has plummeted in a firestorm this year.
Via
Investor's Business Daily
Cassava Sciences Has Value and Is Likely To Proceed to Phase 3
September 17, 2021
SAVA stock still has an implied upside of 67.9% to $78 per share, even if there is a 50% chance that either the shorts or longs are right.
Via
InvestorPlace
46 Biggest Movers From Yesterday
September 15, 2021
Gainers Communications Systems, Inc. (NASDAQ: JCS) jumped 39.4% to close at $9.41 on Tuesday as the company declared a special dividend of $3.50 per share. Onion Global Limited...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
September 14, 2021
Gainers Progenity (NASDAQ:PROG) shares increased by 17.0% to $1.1 during Tuesday's regular session. As of 12:30 EST, this security is trading at a volume of 40.5...
Via
Benzinga
36 Stocks Moving In Tuesday's Mid-Day Session
September 14, 2021
Gainers FuelCell Energy, Inc. (NASDAQ: FCEL) shares jumped 26% to $7.08 after the company reported better-than-expected Q3 results. BELLUS Health Inc. (NASDAQ: BLU) shares...
Via
Benzinga
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
20
21
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.